On a recent episode of Värdeskaparna, NorthX Biologics very own board member Ted Fjällman made a quest appearance.
During the podcast, Ted delves into the biotech industry’s current trends and future directions, sharing his valuable insights and experiences. It’s an enlightening episode for anyone passionate about biotechnology!
Click the link below to listen:
Värdeskaparna with Ted Fjällman
We’re thrilled to share that Janet Hoogstraate, the CEO of NorthX Biologics, has recently appeared in an episode of Q-podden! 🎧
In this engaging podcast, Janet discusses the latest trends and innovations in the biotech industry, offering her unique perspective and expertise. It’s definitely worth a listen for anyone interested in the field!
Click the link below to listen:
We’re excited to announce that Thomas Beck, the Chief Quality Officer (CQO) at NorthX Biologics, has recently been featured in an episode of Q-podden!
In this podcast, Thomas shares valuable insights into the latest advancements and challenges in the field of biologics. It’s a must-listen for anyone interested in the biotech industry!
Click the link below to listen:
In this episode of the Molecule to Market podcast, NorthX Biologics CEO Janet Hoogstraate was invited to discuss the implications of integrating Catalent’s capabilities into Novo Nordisk’s operations and what it means for the broader CDMO sector, in a panel together with other industry experts:
Podcast host Raman Sehgal discusses the pharmaceutical and biotechnology supply chain with Dirk, Brett, John & Janet, focusing on:
With GLP-1 drugs at the forefront of diabetes and obesity treatment, Novo Nordisk’s strategic acquisition of Catalent aims to strengthen its supply chain and boost production capacity to meet global demand. Our guests provide in-depth insights into how this acquisition could shape the future of drug development and outsourcing across the industry.
Listen to the podcast here:
Spotify: https://open.spotify.com/episode/71wNcfTNnlf6EAC89gdQj1
Apple: https://ow.ly/8kNF50PlzOZ
Amazon: https://ow.ly/M3WI50PlzP1
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
The increasingly dynamic and multifaceted landscape of mRNA therapeutics is posing new regulatory and manufacturing challenges. Both startups and established biopharma companies require innovative solutions to help them meet the current demand and plan for the next generation of personalized cancer therapies, vaccines, and other mRNA-based therapeutics.
In this GEN webinar, a panel of industry experts will explore the evolution of mRNA technology and the innovations that are driving the conversation around manufacturing setups and regulatory decisions. During the webinar, panelists will cover diverse aspects of manufacturing optionality, including process considerations, scale, automation, digital tools, and facility design. They’ll analyze how these factors vary between different therapies and explain how they are shaping the manufacturing approach for small and large biopharma companies. They’ll also discuss regulatory considerations for mRNA manufacturing and share their perspectives on managing manufacturing needs from early-stage clinical trials to full-scale production.
Key learnings from the webinar include:
Presenters:
Ola Tuvesson
Chief Technology Officer, NorthX Biologics
Katarina Stenklo
Sr. Product Manager, Global FlexFactory, Cytiva
Sandra Racordon-Pape
Head of Regulatory Science, Cytiva
Joe Barberio
Vice President Technical Operations, Strand Therapeutics
Register to listen on demand here.